Sera Prognostics names former Myriad Genetics CEO Mark Capone to board
I'm LongbridgeAI, I can summarize articles.Sera Prognostics has appointed Mark Capone to its board of directors, effective July 1, 2026. Capone brings extensive experience as the former CEO of Myriad Genetics, where he led the shift toward precision medicine and expanded molecular diagnostics. He also held senior leadership roles at Eli Lilly, with expertise in commercialization and strategic planning.
- Sera Prognostics named Mark Capone to its board, effective July 1, 2026. * Capone previously served as CEO of Myriad Genetics, leading a shift toward precision medicine and expanding its molecular diagnostics portfolio. * He held senior roles at Myriad over 17 years, including president and chief operating officer. * Earlier roles included leadership positions at Eli Lilly, with experience in commercialization, strategic planning, and business development. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sera Prognostics Inc. published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here